FDA Authorizes First CAR-T Cell Clinical Trial for Children with Lupus
The Food & Drug Administration (FDA) has granted Seattle Children’s Hospital the authorization to launch the first CAR-T cell clinical trial in the U.S. for children under 18 years old with systemic lupus erythematosus (SLE).
CAR-T cells are genetically altered cells that are designed to reset the immune system. CAR-T cell therapy targets B cells, which are immune system cells involved in the production of autoantibodies and lupus disease activity. The trial, Reversing Autoimmunity through Cell Therapy, or REACT-01, is planned to begin summer 2024.
Continue to follow the Lupus Foundation of America for updates on REACH-01, as well as other lupus drug development news. Learn more about participating in clinical trials.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.